International Stem Cell Corporation, a California-based biotechnology company, today announced that the United States Patent and Trademark Office (USPTO) has granted the Company a patent for a method of creating pure populations of definitive endoderm, precursor cells to liver and pancreas cells, from human pluripotent stem cells. This patent is a key element of ISCO’s metabolic liver disease program and allows the Company to produce the necessary quantities of precursor cells in a more efficient and cost effective manner.
The patent, 8,268,621, adds to the Company’s growing portfolio of proprietary technologies relating to the development of potential treatments
SANUWAVE Health Inc. received a patent issued by the U.S. Patent and Trademark Office entitled “Use of Pressure Waves for Stimulation, Proliferation, Differentiation and Post-Implantation Viability of Stem Cells.”
The claims of the patent relate to the use of shock waves for stimulation of proliferation inside the body of donor stem cells. The proliferated donor stem cells are then harvested for further laboratory proliferation to create either autologous or allogeneic transplant cells.
In another step, shock waves are used to pre-treat the targeted location for tissue regeneration, to stimulate blood vessel formation and thus increase survival rate for transplanted stem cells.
Oregon Health & Science University’s unique method of transforming a person’s own skin cells into stem cells has officially been patented. The United States Patent and Trademark Office, an agency within the U.S. Department of Commerce, issued the patent earlier this year. Securing a patent is a key step in commercializing discoveries, an important objective for OHSU. Revenue from commercialized discoveries has the potential to bring financial benefit to the university and the state of Oregon.
The procedure, developed by Shoukhrat Mitalipov, Ph.D. at OHSU’s Oregon National Primate Research Center, accelerated efforts to generate stem cell therapies for humans. The